Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET Kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours

NCT05752552 is registered in ClinicalTrials.gov with DeuterOncology as lead sponsor.

NCT NCT05752552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05752552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET Kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours
Lead sponsor
DeuterOncology
Phase
Phase 1
Overall status
Recruiting
Start date
December 20, 2022
Completion date
September 30, 2028
Enrollment
55 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

adult solid tumor, advanced solid tumor, hereditary renal papillary cancer, lung cancer, non-small cell carcinoma, non-small cell lung cancer, refractory tumor